News & Events
- OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
- OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO™ and Its Gene Delivery Platform
- OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma
Designed to Arm the Immune System to Fight Cancer
We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.
Our core technology platform continues to advance through clinical trials for various cancers
Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer